Aspiration: Profile BNL preferred area explorative ED / translational med studies.

Get Started. It's Free
or sign up with your email address
Rocket clouds
Aspiration: Profile BNL preferred area explorative ED / translational med studies. by Mind Map: Aspiration: Profile BNL preferred area explorative ED / translational med studies.

1. Forums / governance to influence initiative

2. Potential Stakeholders

2.1. INTERNAL

2.1.1. ID&V

2.1.1.1. Jacques Bollekens / Jeroen Aerssens Biomarkers

2.1.2. DS

2.1.2.1. Bart VNH

2.1.2.1.1. Readiness cohorts

2.1.2.1.2. Pro-active identification patients based on health records

2.1.3. Maikel Raghoebar (CPU)

2.1.4. Erik Present (AM)

2.1.5. NS

2.1.5.1. Jan Jenssen Egebjerg - neurodegeneration ED

2.1.5.2. Simon Lovestone UK Biobank Biomarkers

2.1.5.3. Diderik

2.1.5.4. Maarten Timmers / Luc V Nueten

2.1.5.4.1. Previous Successful partners?

2.1.5.4.2. Previous unsuccessful partners?

2.1.6. ONCOLOGY

2.1.6.1. B. Bruyninckx - GCDO

2.1.6.2. Ulrike Phillipar - Disc. Biology

2.1.6.3. Peter Hellemans - Clin. Pharmacol?

2.1.6.4. Tine Casneuf - Biomarkers

2.1.7. Vaccines

2.1.7.1. Hanneke Schuitemaker via Nynke

2.1.8. IMMUNOLOGY

2.1.8.1. Cécile Spiertz

2.1.8.2. Mo Lamfkanfi?

2.1.9. PDMS

2.1.9.1. Peter Pruuost

2.1.10. Legistlation

2.1.10.1. Paul Korte ED translation med

2.2. EXTERN

2.2.1. CPUs

2.2.1.1. SGS - Bel Stuivenberg

2.2.1.2. Jan Palfijn Merksem

2.2.1.3. CHDR - Leiden

2.2.1.3.1. Commercial phase I unit

2.2.2. Universities

3. Scope

3.1. TA focus

3.1.1. ED Onco

3.1.2. Vaccines

3.1.3. NS

3.2. Initial: Phase 0 until Phase II Proof of relevance

3.2.1. To be further refined after interviews TAs & prioritization.

4. Assumptions & contraints

5. Objectives

5.1. Objective#1: Identify & analyse JBENE strengths, weaknesses, opportunities & threats within ED space (Phase 0 - Phase II proof of relevance) for next 1-3 years

5.1.1. Map internal stakeholders with decision making power / budget to get buy in.

5.1.1.1. Strenghts, weaknesses, opportunities & roadblocks?

5.1.1.2. Needs?

5.1.1.3. Collaborations? - Lessons learned

5.1.1.4. Projects in pipeline

5.1.1.5. Call for Core team to Bert GCDO - Maikel CPU - J. Bollekens representative - Vaccines Hanneke

5.1.2. Mapping external landscape ED Phase 0 - Phase II proof of relevance

5.1.2.1. CPUs capabilities - where focus ED space

5.1.2.2. Hospitals - where focus ED space - innovative concepts

5.1.2.3. Academic centra

5.1.2.4. Support for Alliance management to bridge towards these organizations? - Shape certain initiatives?

5.2. Objective#2: Prioritize on max 2-3 challenges identified in obj#1 in collaboration of core team, AM

5.2.1. Set priorities taken into account multiple factors

5.2.1.1. Lessons learned internal collaborations

5.2.1.2. Competing initiatives - efforts should complement or support existing efforts JBENE

5.2.1.3. Common interests for > 1 TA is an asset

5.2.1.4. Feedback alliance mgt about inputs BNL ecosystem (academic centers;

5.3. Objective#3 Testing innovative tools / Profile innovative culture

5.3.1. Support JCI with pilot studies

5.3.2. Expected results / acceptance criteria

5.3.3. Profile innovative culture

5.3.3.1. Kiss & Kill trials

5.3.3.1.1. CHDR

5.3.3.1.2. CPU Merksen

6. "SWOTs" BNL ecosystem

6.1. Opportunities

6.1.1. facilitating Legislation

6.1.1.1. To be changed? - Nynke

6.1.1.1.1. Follow up Paul Korte?

6.1.2. Mindset/ willingness PI

6.1.3. proximity universities/ biotechs, CPUs

6.1.4. Patient data access

6.2. Strenghts

6.2.1. JBENE capabilities Discovery / ED / PDMS

6.3. Weakness

6.4. Threats